[GFO]The $20.4 million in interim applicant funding approved for Cameroon (first announced in this GFO article) will be used exclusively to procure antiretrovirals (ARVs), related health products and medicines to treat opportunistic infections. The money will be added to an existing HIV grant, CMR-011-G11-H, for which the principal recipient is the Ministry of Public Health (MPH), to be used over the remaining ten months of Phase 1 of that grant.
Related posts
-
New OLI Systems platform V11 democratizes electrolyte modeling with revolutionary cloud platform; new, rigorous chemistry insights and software innovations enhance sustainability, reliability, and efficiency
Cloud Apps, Cloud APIs, Optimizer and Bulk Data Input fuel industrial digital transformation PARSIPPANY, N.J., Dec.... -
IOM COVID-19: Impact On Key Locations of Internal Mobility – Bi-Weekly Analysis, 4 November 2020
Executive summary The current COVID-19 pandemic has affected global mobility both in terms of international mobility... -
UNOWAS Magazine N12 – October 2020
Following Togo where presidential elections were held last February, five more presidential elections are planned in...